A detailed history of Bvf Inc transactions in Allakos Inc. stock. As of the latest transaction made, Bvf Inc holds 16,552,417 shares of ALLK stock, worth $14.7 Million. This represents 0.34% of its overall portfolio holdings.

Number of Shares
16,552,417
Previous 16,552,417 -0.0%
Holding current value
$14.7 Million
Previous $16.6 Million 35.0%
% of portfolio
0.34%
Previous 0.51%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 15, 2024

BUY
$1.02 - $3.23 $8.16 Million - $25.8 Million
8,000,000 Added 93.54%
16,552,417 $20.9 Million
Q3 2023

Nov 14, 2023

SELL
$2.13 - $5.55 $213,000 - $555,000
-100,000 Reduced 1.16%
8,552,417 $19.4 Million
Q2 2023

Aug 14, 2023

BUY
$3.6 - $5.25 $9.33 Million - $13.6 Million
2,592,170 Added 42.77%
8,652,417 $37.7 Million
Q1 2023

May 15, 2023

BUY
$4.3 - $8.27 $4.53 Million - $8.71 Million
1,053,326 Added 21.04%
6,060,247 $27 Million
Q3 2022

Nov 14, 2022

BUY
$3.02 - $6.12 $15.1 Million - $30.6 Million
5,006,921 New
5,006,921 $30.6 Million

Others Institutions Holding ALLK

About Allakos Inc.


  • Ticker ALLK
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 84,726,096
  • Market Cap $75.4M
  • Description
  • Allakos Inc., a clinical stage biopharmaceutical company, develops therapeutics that target immunomodulatory receptors present on immune effector cells in allergy, inflammatory, and proliferative diseases. The company's lead monoclonal antibody is lirentelimab (AK002), which is in a Phase III study for the treatment of eosinophilic gastritis and...
More about ALLK
Track This Portfolio

Track Bvf Inc Portfolio

Follow Bvf Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Bvf Inc, based on Form 13F filings with the SEC.

News

Stay updated on Bvf Inc with notifications on news.